

source: <https://doi.org/10.7892/boris.119686> | downloaded: 6.5.2023

1 **The IGF pathway is activated in insulinomas but downregulated in**
2 **metastatic disease**
3 **Mieke E. R. Henfling¹, Aurel A. Perren², Anja M. Schmitt², Christiane M.**
4 **Saddig³, Achim A. Starke³, Robert G. Riedl⁴, Yvonne M.H. Versleijen-**
5 **Jonkers⁵, Diana M. Sprij-Mooij⁶, Frans C.S. Ramaekers¹, Leo J. Hofland⁶,**
6 **Ernst-Jan M. Speel⁴**

7 ¹Department of Molecular Cell Biology, GROW-School for Oncology & Developmental
8 Biology, Maastricht University, Maastricht, The Netherlands
9 ²Institute of Pathology, University of Bern, Bern, Switzerland.
10 ³ Insulinoma and GEP-Tumor Center Neuss-Düsseldorf, Klinik für Endokrine Chirurgie,
11 Lukaskrankenhaus Neuss, Germany
12 ⁴Department of Pathology, GROW-School for Oncology & Developmental Biology,
13 Maastricht University Medical Centre, Maastricht, The Netherlands
14 ⁵ Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The
15 Netherlands
16 ⁶Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University
17 Medical Center Rotterdam, Rotterdam, The Netherlands
18

19 **Running title:** EGFR, IGF and mTOR pathway gene expression in insulinomas
20 **Wordcount text:** 4686
21 **Keywords:** Insulinoma, pancreatic neuroendocrine tumor (PanNET), EGFR, IGF2, IGF1R,
22 mTOR signaling, metastatic disease

23
24 Correspondence to:
25 Ernst-Jan M. Speel, PhD, Department of Pathology, Maastricht University Medical Centre,
26 P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.
27 Phone: +31433874614
28 Fax: +31433876613
29 E-Mail: ernstjan.speel@mumc.nl

30
31
32
33
34

Abstract

Clinical and molecular studies have implicated epidermal growth factor receptor (EGFR), insulin-like growth factor (IGF) and target of rapamycin (mTOR) signaling pathways in the regulation of pancreatic neuroendocrine tumor (PanNET) growth. Interpretation and comparison of these studies is complex due to clinical and molecular tumor heterogeneity. We therefore focused in this study on insulinomas, which we examined for mRNA and protein expression of EGFR, IGF and mTOR signaling pathway components by quantitative real-time PCR (n=48) and immunohistochemistry (n=86). Findings were compared with normal pancreatic islets and correlated with histopathological data and clinical outcome. Insulinomas showed low *EGFR* and high *IGF2* expression. *IGFBP2*, *IGFBP3* and *IGFBP6* mRNA levels were 2-4 folds higher than in islets. High protein expression of IGF2, IGF1R and INSR (in 51-92% of the tumors) and low to moderate expression of mTORC1 pathway proteins p-S6k and p-4EBP1 (7-28% of the tumors) were observed. Correlations were found between 1) *ERK1* mRNA expression and that of numerous IGF pathway genes, 2) p-ERK and IGF1R protein expression and 3) decrease of IGF pathway components and both metastatic disease and shorter 10 years disease free survival. In conclusion, our observations suggest that high expression of IGF signaling pathway components is a hallmark of insulinomas, but does not necessarily lead to increased mTOR signaling. Reduced expression of IGF pathway components may be an adverse prognostic factor in insulinomas.

Introduction

Over the past years advances have been made in understanding the biology and clinical behavior of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a heterogeneous group of tumors arising from the diffuse neuroendocrine system (Oberg 2012, Muniraj *et al.* 2013). The estimated annual incidence of NETs in the USA increased 6.4 fold between

1973 and 2012, with an incidence rate of 3.56/100,000 in gastroenteropancreatic sites (Dasari *et al.* 2017). GEP-NETs can be divided, based on clinical manifestations, into functioning (syndrome-related) and non-functioning tumors. Today, PanNETs are treated by surgery, biotherapy, chemotherapy and/or molecular targeted therapy using multidisciplinary therapeutic management. Since 2011 the FDA approved the mammalian target of rapamycin (mTOR) inhibitor Everolimus for the treatment of progressive PanNETs and well-differentiated, non-functional GEP-NETs and lung-NETs (RADIANT-3 and -4 studies) (Yao *et al.* 2011, Yao *et al.* 2016). mTOR regulates cell survival, proliferation and motility, and also senses cell energy status (Gentzler *et al.* 2012). Because of the heterogeneity of PanNETs, analysis of the underlying molecular biology is essential for successful targeted treatment. The basis of positive treatment results for Everolimus is derived from a number of studies implicating mTOR pathway alterations in the proliferation of PanNETs. (Jiao *et al.* 2011) found mutations in the mTOR pathway genes *PTEN* and *TSC2* in 14% of (non-functioning) PanNETs. Moreover, (Missiaglia *et al.* 2010) reported downregulation of *PTEN* and *TSC2*, inhibitors of the mTOR pathway, in up to 70% of non-functioning and functioning PanNETs, including insulinomas. Whole genome sequencing of insulinomas revealed mutations in the gene *YY1*, a target of mTOR, in 30% of the tumors (Cao *et al.* 2013). Finally, several immunohistochemical studies showed positivity for mTOR pathway proteins p-mTOR (range 60-70%), p-S6K (40-80%), and p-4EBP1 (30-90%) in GEP-NETs (Kasajima *et al.* 2011, Zhan *et al.* 2012, Qian *et al.* 2013). However, interpretation and comparison of these studies is complex due to the fact that GEP-NETS/PanNETs comprise heterogeneous tumor sub-types with different clinical and molecular characteristics, and studies have used different diagnostic tools and evaluation criteria to detect alterations in the mTOR pathway.

The mTOR pathway can be activated by various upstream stimuli, including epidermal growth factor receptor (EGFR) and the insulin-like growth factor (IGF) signaling system, which play a pivotal role in cancer development and progression. EGFR activation promotes cell proliferation via MAPK and PI3K signaling routes, and indications for a role of EGFR signaling in PanNETs have been reported. Immunohistochemical analysis of

EGFR expression showed positivity in 30-65% of mixed populations of PanNETs (Srivastava *et al.* 2001, Papouchado *et al.* 2005, Bergmann *et al.* 2009). The IGF signaling system includes the ligands IGF1 and IGF2, the receptors IGF1R, IGF2R and insulin receptor (INSR), and 6 IGF binding proteins (IGFBP1 to 6) (Lodhia *et al.* 2015). Deregulation of the IGF signaling system, for example by upregulation of IGF1R, IGF2 and IGFBP2, has been reported in several malignancies, including GEP-NETs/PanNETs and insulinomas (Wulbrand *et al.* 2000, Dejeux *et al.* 2009, Ludovini *et al.* 2009, Livingstone 2013).

In this study we evaluated mRNA and protein expression patterns of EGFR and IGF signaling pathway components that may regulate the mTOR pathway, as well as the mTORC1 pathway downstream effectors p70S6 Kinase (S6K) and 4E-BP1 (4EBP1) in a large series of insulinomas. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) data were correlated with each other, with histopathology and with clinical patient and follow-up data.

Materials and methods

A detailed description of materials and methods can be found in Supplementary Materials and Methods.

Patient samples

Detailed data on insulinoma patient's age, sex, disease stage and tumor grade and size are provided as Supplementary Table 1 (Jonkers *et al.* 2007, Marinoni *et al.* 2014). All insulinoma patients had hyperinsulinism followed by a hypoglycaemia syndrome. The initial treatment consisted of surgical removal of the primary tumor, and if present liver and/or lymph node metastases. Follow-up treatment for patients with metastatic disease included surgery, Transarterial Embolization or Transarterial Chemoembolization. The tumors were all sporadic, not associated with MEN1 syndrome and classified according to the World Health Organization 2010 staging and grading system.

From 48 insulinoma patients snap frozen tumor tissue was available for RNA analysis, and from 26 patients also formalin-fixed, paraffin-embedded material. Two paraffin-embedded tissue micro arrays (TMAs) were available for immunohistochemical analysis, containing 49 insulinomas (TMA1) and a second TMA with 11 additional insulinomas (TMA2). TMA1 furthermore contained 92 additional PanNETs (12 gastrinomas, 11 glucagonomas, 10 vipomas and 59 non-functioning PanNETs), of which data can be found in Supplementary Table 6. Patient material was used according to the Code for Proper Secondary Use of Human Tissue in The Netherlands (<https://www.federa.org/>, update 2011) and according to the cantonal ethics committee of Bern (KEK-BE 105-2015).

RNA isolation

Total RNA was isolated from snap frozen insulinomas using the Qiagen RNeasy Mini Kit, and had a RIN value ≥ 6.5 .

Control MPV™ Total RNA from normal human pancreas, liver, lung and adrenal gland (Stratagene) and total RNA from normal, single donor human pancreatic islets (a gift of Dr E. de Koning, Leiden University Medical Center, The Netherlands) were included as controls.

Quantitative Real-Time PCR

Total RNA was converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). qRT-PCR reactions were performed using two commercially available SYBR green mixes, iQ™ SYBR® Green Supermix (BioRad) and SensiMix™ SYBR & Fluorescein Kit (BioLine). All primers (Supplementary Table 2) were purchased from Biolegio .

Immunohistochemistry

Immunohistochemical staining on freshly cut 4 µm-thick formalin-fixed, paraffin embedded tissue sections was performed using primary antibodies against EGFR, IGF2, IGF1R, INSR, p-AKT, p-ERK, p-S6K and 4-EBP1. Detailed information on antibodies and staining conditions can be found in Supplementary table 3.

Immunohistochemical staining was scored as: 0, absent; 1, weakly positive in ≥10% of cells; 2, moderately positive in ≥10% of cells, 3, strongly positive in ≥10% of cells.

Statistical analysis

Statistical analysis was performed using SPSS version 20 (IBM). Mean relative gene expression levels between groups were compared with the F-test and Student t-test.

Associations between relative gene expression levels and immunostaining levels were determined using Pearson's correlation. All *P*-values were considered statistically significant if ≤ 0.05 in two-sided tests.

Survival curves were created using the Kaplan–Meier method, the log-rank test was used to test for differences between subgroups. Details on assessment of disease free or overall survival rates can be found in the Supplementary Materials and Methods. Cox-regression was used for multivariate analysis.

Results

mRNA expression in insulinomas

Neuroendocrine markers

From 48 insulinomas mRNA was analyzed. To check for the endocrine nature of the tumors the relative mRNA expression levels of insulin (*INS*), chromogranin (*CGA*) and synaptophysin (*SYP*) were analyzed by quantitative RT-PCR (qRT-PCR). In addition, mRNA from normal human tissues (whole pancreas, pancreatic islets, liver, lung and adrenal gland) was analyzed as controls. Expression levels were normalized to glucuronidase beta (*GUSB*), which exhibited the most stable expression level in all samples after comparing the expression levels of 4 housekeeping genes. Table 1 shows high mean and median expression levels of *INS*, *CGA* and *SYP* mRNA (8351, 89 and 2.3 normalized to *GUSB*, respectively), consistent with the neuroendocrine character of insulinomas. In normal pancreatic islets the mRNA expression levels of *INS*, *CGA* and *SYP* were respectively 4151, 15 and 0.5. In normal pancreatic tissue the mRNA levels for these genes were significantly lower. Normal adrenal mRNA showed a high expression level of *CGA* (57) and *SYP* (1.3), but very low *INS* expression (0.2). In normal liver and lung tissue very low mRNA expression levels of *CGA*, *SYP* and *INS* were found (data not shown; analyses of normal controls were performed three times in duplicate). When compared to normal pancreatic islets the mean expression levels of *INS*, *CGA* and *SYP* mRNA in insulinomas showed a 2.0, 6.0 and 4.8 fold increase, respectively (Table 1).

EGFR, ERK and AKT

Since EGFR signaling via MAPK and AKT pathways has been reported to be active in PanNETs, we examined the mRNA expression levels of *EGFR*, *ERK1*, *ERK2* and *AKT* in the 48 insulinomas. *EGFR* mRNA expression was low (0.10), with a relative expression of 0.15 as compared to normal pancreatic islets (Table 1). *ERK1*, *ERK2* and *AKT* mRNA

expression levels were 1.1, 1.6 and 2.6, respectively. *ERK1* expression was at the same level as in normal pancreatic islets, while the relative expression levels of *ERK2* and *AKT* showed a 0.3 and 0.2 fold decrease.

IGF pathway

Table 1 shows the mRNA expression levels of IGF pathway-related genes in insulinomas. In contrast to very low *IGF1* levels, the mean mRNA expression level of *IGF2* is 1.5, which is a 12.4 fold increase compared to normal pancreatic islets (median: 3.5 fold increase). *IGFBP2* has an expression level of 4.8, which is 4.0 fold higher than in normal pancreatic islets. Despite the fact that *IGFBP3* and *IGFBP6* showed expression levels of 0.21 and 0.23 (normalized to *GUSB*), their relative expression was 2-3 folds higher than in normal pancreatic islets. The other IGF pathway genes showed low expression levels (0.01-0.2).

mTOR pathway

The mean mRNA expression levels of *MTOR* and *RPS6KB1* (coding for S6K protein) (were low (0.01-0.02) in insulinomas, whereas *EIF4EBP1* (coding for 4EBP1 protein) is expressed at the level of *GUSB* (Table 1). In normal pancreatic islets all 3 genes showed a 0.4-0.6 fold decreased mRNA expression level.

In conclusion, insulinomas show low expression levels of *EGFR* mRNA, high expression of *IGF2*, a 2-4 fold increased expression of *IGFBP2*, *IGFBP3* and *IGFBP6*, and a twofold reduced expression of *MTOR*, *RPS6KB1* and *EIF4EBP1*, as compared to pancreatic islets.

Correlations between mRNA expression patterns

Pearson correlation analysis between mRNA expression levels of different signaling pathway genes is shown in Supplementary Table 4. Correlations between substantially expressed genes include those 1) between *ERK 1*, *ERK2* and *AKT* and 2) between *ERK1* and IGF pathway genes *IGFBP2* (inverse correlation), *IGFBP6*, and all receptors (detailed

information in supplementary Table 4). *IGF2*, *IGFBP3* (except for *SYP*) and *EIF4EBP1* expression levels did not correlate with the other analyzed genes.

Protein expression in insulinomas

EGFR, ERK and AKT

Immunostaining was performed on 86 insulinomas, including 26 that were also analyzed for mRNA expression levels (see above), and 60 cases present as single or duplicate cores on the TMAs. All tumors were negative for EGFR, which is in agreement with the low assessed EGFR mRNA expression levels. As a positive control a human premalignant laryngeal lesion was used, showing strongly positive membranous staining. In normal human pancreas a low number of acinar cells showed a weakly positive membranous staining, whereas the islet cells were negative for EGFR (Table 2; Fig. 1, A-C).

Table 2 shows the IHC data for p-AKT and p-ERK. A lung carcinoma harboring a K-ras exon 2 mutation served as positive controls (Supplementary Figure 1, A and B respectively). A moderate to strong nuclear p-AKT expression was seen in normal pancreatic islet cells, whereas the acinar cells were negative. In normal pancreas no p-ERK could be detected. Moderately to strongly positive nuclear p-AKT staining was observed in 22% and nuclear p-ERK in 32% of insulinomas (Fig. 1, D-F). Twenty-four % of the insulinomas showed neither nuclear nor cytoplasmic p-ERK staining; 36% were negative for p-AKT. Moderate to strong simultaneous expression of nuclear p-AKT and p-ERK was found in 10% of the tumors, while in 22% no co-expression of nuclear p-AKT and p-ERK could be detected (double-negative).

IGF pathway proteins

IHC results for IGF pathway proteins IGF2 and receptors IGF1R and INSR are shown in Table 2 and Fig. 1, G-O. In 92% of the insulinomas a strong cytoplasmic, diffusely granular pattern of IGF2 was observed. A similar pattern of lower intensity was seen in normal pancreatic islet cells, whereas acinar cells showed a strong, aggregated

extracellular IGF2 localization, which could be a sign of internalization of IGF1R and/or INSR after ligand binding (Rajapaksha & Forbes 2015).

Tumors indeed exhibited high, diffuse cytoplasmic expression levels of IGF1R and INSR (78% and 83%, respectively), while in 51% of the cases also a membranous IGF1R staining and in 38% a perinuclear localization of INSR was observed.

These patterns could also be recognized in the normal pancreas, i.e. the islet cells showed a granular cytoplasmic IGF1R and INSR expression pattern, whereas the acinar compartment showed a membranous IGF1R localization, and a cytoplasmic INSR expression with perinuclear localization.

These data indicate that the IGF pathway is active in insulinomas.

mTORC1 pathway proteins p-S6K and p-4EBP1

Table 2 and Figure 2 (A-F) show the IHC results for p-S6K and p-4EBP1. Normal human colon tissue served as positive control (Supplementary Figure 1, C and D).

In 28% of insulinomas a weakly to moderately positive cytoplasmic p-S6K staining pattern was seen. Also 28% of tumors showed nuclear staining. Normal pancreatic islets showed the same staining pattern but with lower intensity. In contrast, in approximately 75% of normal pancreatic acinar cells a moderately to strongly positive perinuclear and/or diffuse nuclear p-S6K staining was detected. Interestingly, in tumor-adjacent pancreatic tissue we observed a stronger p-S6K staining in acinar and islet cells than in normal control pancreatic tissue (data not shown).

Only 37% of insulinomas exhibited a weakly to moderately positive nuclear p-4EBP1 staining, and in 22% also cytoplasmic staining was detected (Table 2). Normal pancreatic islets did not show p-4EBP1 expression, and areas, predominantly at the periphery of lobules, showed a moderately to strongly positive diffuse cytoplasmic, and in 90% also strong nuclear, immunostaining in acinar cells (Fig. 2, D-E). Strikingly, exocrine pancreatic tissue adjacent to the tumor often displayed a stronger nuclear and cytoplasmic immunostaining.

In conclusion, insulinomas show high expression levels of IGF2, IGF1R and INSR, no EGFR expression and low levels of phosphorylated mTORC1 pathway proteins.

Positive correlations between protein expression patterns

Pearson correlation analysis of protein expression levels shows a correlation of IGF2 with cytoplasmic IGF1R ($p=0.019$). The latter also correlates with nuclear p-ERK ($p=0.003$), which in turn correlates with nuclear p-AKT ($p=0.011$) and nuclear p-S6K ($p=0.002$). In addition cytoplasmic INSR correlates with nuclear p-S6K ($p=0.024$) (Supplementary table 5).

Correlation of mRNA and protein expression with clinicopathologic parameters in insulinomas

Mean relative gene expression levels of insulinoma subgroups were compared using Student's t-test (Table 3A). Of the 20 genes analyzed, only the relative expression level of *IGF2R* compared to normal pancreatic islets was significantly lower in grade 2/3 than in grade 1 insulinomas ($p=0.039$). A decrease in expression in grade 2/3 tumors was also seen for *IGF1R*, *INS* and *IGF2*, although not statistically significant. At the protein level (Table 3B) a significantly lower membranous INSR and cytoplasmic p-4EBP1 staining intensity was found in grade 2/3 as compared to grade 1 insulinomas ($p=0.004$ and $p=0.001$, respectively). The mean mRNA expression level of *INS* relative to normal pancreatic islets was significantly lower in metastatic insulinomas than in non-metastatic ($p<0.0001$). In contrast, the relative expression of *IGFBP3* was higher in metastatic tumors, although the difference was not statistically significant. The protein expression levels of IGF2, cytoplasmic IGF1R and INSR, membranous INSR and cytoplasmic p-S6K were significantly lower in metastatic tumors than in non-metastatic tumors ($p=0.001$, $p=0.026$, $p=0.035$, $p=0.004$ and $p=0.030$, respectively).

Comparison of the mean mRNA expression levels between tumors $<$ and ≥ 2 cm revealed *INS* and *4EBP1* mRNA levels to be significantly lower in tumors ≥ 2 cm ($p=0.009$ and $p=0.003$, respectively). This was also observed for IGF2 protein expression ($p=0.001$). A higher disease stage (stage IV versus stage I+II) correlated with a lower expression of *INS*, *IGF2* and *IGF1R* mRNA, as well as IGF2, p-ERK (nuclear and cytoplasmic), cytoplasmic IGF1R and in membranous INSR protein.

In conclusion, insulinomas appear to reduce IGF pathway gene expression both at the mRNA and protein level in relation to tumor grade, metastatic potential, size and disease stage.

Correlation of mRNA and protein expression and clinicopathologic parameters with survival in insulinomas

Lower mRNA expression levels of *INS*, *IGF1R* and *INSR-A* ($p \leq 0.019$ for disease free and $p \leq 0.032$ for overall survival) and higher levels of *IGFBP3* ($p < 0.0001$ for disease free and $p = 0.001$ for overall survival) correlated with shorter 10 years survival (Figure 3 and suppl. Fig 2).

Lower protein levels of cytoplasmic IGF2, IGF1R and INSR ($p \leq 0.035$ for disease free survival; $P \leq 0.033$ for overall survival) correlated with shorter 10 years survival rates (Fig 4 and suppl. Fig 3).

Univariate analysis of clinicopathological parameters of tumors showed very strong associations of grade, metastatic disease, tumor size and disease stage with both 10 years disease free and overall survival ($p < 0.0001$) (Fig 3 and Supplementary Fig 2 E-H, and Fig 4 and Suppl Fig 3 D-G).

In Table 4 a summary of parameters that correlate with disease outcome in univariate analysis results is shown.

When comparing high versus low gene expression of either *INS*, *IGF1R*, *INSRA* or *IGFBP3* with grade, metastatic disease and tumor size in multivariate analysis no significant associations were found. In multivariate analysis of moderate versus high IGF2 protein

expression, grade and tumor size, grade ($p=0.024$, HR 6.81) and tumor size ($p=0.022$, HR 17.77) were significantly correlated with 10 year survival. When comparing IGF1R (high versus low expression) with grade and tumor size in multivariate analysis only tumor size ($p=0.032$, HR 7.03) correlated with 10 year survival. This was also found when comparing INSR (high versus low expression) in multivariate analysis with grade and tumor size (tumor size: $p=0.007$, HR 9.31).

Protein expression analysis in PanNETs other than insulinomas

We also analyzed protein expression in 92 PanNETs other than insulinomas, which were available on the TMA1. Data evaluation and analysis are available as supplementary data (Suppl Results, Suppl Tables 6, 7 and 8).

Discussion

Since PanNETs are a heterogeneous group of neoplasms, understanding the underlying molecular biology of the different subgroups is essential to offer adequate treatment (Cives *et al.* 2016). Our study focused on mRNA and protein expression of EGFR, IGF and mTOR signaling pathway components in insulinomas. We found that, compared to pancreatic islets, insulinomas show low expression levels of *EGFR* mRNA, high expression of *IGF2*, a 2-4 fold increased expression of *IGFBP2*, *IGFBP3* and *IGFBP6*, and a twofold reduced expression of *MTOR*, *RPS6KB1* and *EIF4EBP1*. At the protein level, high expression levels of IGF2, IGF1R and INSR were detected, whereas no EGFR and relatively low levels of mTOR pathway proteins were observed. Correlation of expression data with clinicopathological data revealed a decrease of several IGF pathway components in relation to tumor grade, metastatic disease, tumor size and disease stage. Low mRNA expression levels of *IGF2*, *IGF1R* and *INSR-A* but high levels of *IGFBP3* correlated with shorter 10 years overall and disease-free survival. Decreased protein

expression of IGF2, cytoplasmic IGF1R and INSR also correlated with shorter survival rates.

Activated EGFR enhances tumor growth, invasion and metastatic spread and promotes cell survival. Abnormal expression of (mutated) EGFR is often found in neoplasms, particularly in breast, non-small-cell lung, head and neck and colorectal cancer, which is utilized in targeted therapy with TKIs or antibodies directed against EGFR (Ciardiello & Tortora 2008, Garraway & Janne 2012). An initial phase II trial using gefitinib treatment of PanNETs, however, did not show much efficacy, i.e. no objective responses and a 6-months progression-free survival of 10% for islet cell carcinomas (Hobday *et al.* 2006). In our study we found low levels of *EGFR* mRNA and neither detectable protein expression in insulinomas and normal pancreatic islets. These data thus may explain the low efficacy of EGFR inhibitors in the treatment of PanNETs. Nevertheless, other studies have reported detectable expression of EGFR in 18-66% of the tumors (Wulbrand *et al.* 1998, Srivastava *et al.* 2001, Fjallskog *et al.* 2003, Papouchado *et al.* 2005, Gilbert *et al.* 2013), with low expression in benign PanNETs and high expression rates in both well-differentiated PanNETs and poorly differentiated pancreatic neuroendocrine carcinomas (Bergmann *et al.* 2009). In these studies, however, mixed groups of PanNETs were subjected to immunohistochemical staining protocols differing in, amongst others pretreatment steps, primary antibodies, and evaluation criteria. We have utilized a commonly used EGFR immunostaining protocol and a primary EGFR-specific antibody, resulting in intense EGFR membrane staining in head and neck premalignancy control specimens as well as in pancreatic ducts adjacent to negative insulinomas. Based on our results we can conclude that EGFR signaling does not play a pivotal role in insulinoma carcinogenesis and progression.

Our most striking finding was that 92% of insulinomas stained moderately to strongly positive for the IGF2 protein, which implicates autocrine activation of the IGF pathway in tumorigenesis, also reported by others (Samani *et al.* 2007, Werooha & Haluska 2012, Denduluri *et al.* 2015). This corresponded well with the 12.4 fold higher *IGF2* mRNA level in insulinomas compared to normal pancreatic islets. *IGF2* is an imprinted gene,

expressed primarily from the paternal allele. Methylation of the *IGF2* regulatory regions has been reported in many cancers, resulting in loss of imprinting and protein overexpression (Murphy *et al.* 2006, Cerrato *et al.* 2008, Dejeux *et al.* 2009, Livingstone 2013, Creemers *et al.* 2016). (Dejeux *et al.* 2009) reported hypermethylation of the differentially methylated region 2 (DMR2) as a specific event in insulinomas, leading, in a subset of the samples, to *IGF2* mRNA overexpression compared to normal pancreatic tissue, other PanNETs (gastrinomas and non-functioning) and small intestinal endocrine tumors. At the protein level they found moderate to high expression levels in 14/28 insulinomas. The use of a different primary antibody and unspecified immunostaining procedure might explain the lower frequency of IGF2 positive insulinomas. (Hoog *et al.* 2001) detected higher levels of IGF2 protein in 16 out of 18 insulinomas, which is in accordance with our findings. In contrast to *IGF2*, the mRNA expression of *IGF1* was very low in insulinomas and not detectable in normal pancreatic islets.

The IGF signaling pathway is activated by binding of the ligands IGF1, IGF2 or insulin to their respective receptors, IGF1R and INSR. Posttranscriptional alternative splicing of INSR results in two isoforms, INSR-A (which lacks exon 11) and INSR-B. IGF2 binds with similar affinity both to IGF1R and INSR-A, which promotes cell growth, proliferation and survival (Chao & D'Amore 2008). IGF1R and INSR are overexpressed in a variety of cancers, including breast, prostate, osteosarcoma and thyroid carcinomas (Lodhia *et al.* 2015). In our study we found moderate to strong cytoplasmic and membranous IGF1R and cytoplasmic INSR protein expression in 51%, 78% and 83% of the insulinomas respectively, which was at least similar, or stronger in staining intensity than observed in pancreatic islets. Since we found a correlation between IGF1R and high IGF2 protein expression levels, these data suggest the presence of an autocrine proliferative loop in insulinomas, as described for other cancer types (Bergman *et al.* 2013, Livingstone 2013).

Binding of IGF1 or IGF2 to IGF1R or INSR leads to autophosphorylation of the β subunit tyrosine kinase and recruitment of INSR substrates (IRS), inducing activation of the MAPK/ERK and PI3K/AKT signaling pathways (Alvino *et al.* 2011). Phosphorylation of AKT

leads to activation of mTOR and downstream effectors of mTORC1 S6K and 4EBP1, both
 regulators of mRNA translation and involved in cell proliferation and survival (Robbins &
 Hague 2015). Although 51 and 83% respectively, of the insulinomas in our study express
 IGF1R and INSR protein, only 22% and 32% respectively, strongly express nuclear p-
 AKT and p-ERK, and 4 and 19% respectively, express p-S6K and p-4EBP1. Interestingly,
 a positive correlation was found between cytoplasmic IGF1R expression on the one hand
 and IGF2 and nuclear p-ERK on the other. Also at the mRNA level a correlation was
 observed between *AKT*, *ERK1*, *RPS6KB1* and *MTOR*. The fact that IGF1R signaling does
 not necessarily results in AKT/mTOR signaling might be the result of an intact PTEN
 expression in about two third of the tumors, inhibiting PI3K and subsequent downstream
 signaling. Reduced PTEN expression or altered subcellular localization has been reported
 to activate PI3K/AKT/mTOR signaling in PanNETs (Perren *et al.* 2000, Missiaglia *et al.*
 2010), which might have occurred in the remaining one third of the insulinomas in our
 study. In a pilot study of 10 cases we indeed observed loss of nuclear PTEN expression,
 as compared to normal islets, in 4cases with p-AKT and p-S6K expression (Data not
 shown). (Komori *et al.* 2014) also found active mTOR signaling in 22-35% of a group of
 14 insulinomas tested for amongst others p-mTOR, p-S6K and p-4EBP1. The percentage
 of tumors exhibiting active AKT/mTOR signaling varies significantly in different studies
 due to different PanNET subgroups tested, as well as different antibodies and cut-off
 criteria for positivity used (Ghayouri *et al.* 2010, Kasajima *et al.* 2011, Qian *et al.* 2013).
 It is tempting to speculate that p-AKT and/or p-S6K are putative predictive markers of
 response to Everolimus. A recent study on PanNETs indeed showed anecdotal evidence of
 p-AKT for this role in a primary cell culture model for response to Everolimus (Falletta *et al.*
 2016).
 We observed a decreased level of several IGF pathway components in relation to tumor
 grade, metastatic disease, tumor size and and disease stage. The protein expression
 levels of IGF2, cytoplasmic IGF1R, cytoplasmic and membranous INSR, and cytoplasmic
 p-S6K were significantly lower in tumors from patients with metastatic disease than from
 those with non-metastatic disease. Also the mean mRNA expression levels of *INS* was

significantly lower in patients with metastatic insulinomas as compared to non-metastatic insulinomas. This finding is furthermore reflected in the lower levels of these IGF pathway proteins and their mRNAs in association with shorter 10 years disease-free survival and overall rates. A decrease in both IGF1R protein and gene expression levels has been described before in esophageal adenocarcinoma, colorectal and breast cancer (Schnarr *et al.* 2000, Allison *et al.* 2007, Kuklinski *et al.* 2011, De Bruijn *et al.* 2015) and might reflect a dedifferentiation process. Indeed, two recent genomic studies have identified distinctive m(i)RNA expression profiles, separating PanNET with liver metastases (metastasis-like primary tumor subtype) from well-differentiated PanNETs (well-differentiated islet/insulinoma tumor subtype), further underscoring dedifferentiation to be reflected in gene expression signatures (Sadanandam *et al.* 2015, Scarpa *et al.* 2017). Decreased insulin signaling was one described hallmark of mouse metastasis like primary PanNET (Sadanandam *et al.* 2015)). It remains to be studied whether the changes in gene expression seen in insulinomas reflect a different entity or are the result of tumor progression.

An interesting finding was that the shorter 10 years overall and disease-free survival rates also correlated with higher levels of *IGFBP3* mRNA in insulinomas. This gene belongs to a family of 6 IGF binding proteins, which function as transport proteins for IGF1 and IGF2 in the peripheral circulation, and in this way limit the bioavailability of IGFs, as well as modulators of cell function via amongst others IGF1R-dependent mechanisms (Baxter 2014). *IGFBP3* has been proposed to function as either tumor promotor or suppressor (Baxter 2014). On the one hand overexpression is detected in association with tumor progression in many tumor types, such as head and neck carcinoma (Marimuthu *et al.* 2013), melanoma (Xi *et al.* 2006) or renal clear cell carcinoma (Takahash *et al.* 2005), and on the other hand (Ren *et al.* 2007) found a higher *IGFBP3* mRNA expression in benign as compared to malignant breast tumors. In agreement with our study, (Hansel *et al.* 2004) found higher expression levels of *IGFBP3* in well differentiated PanNETs of patients with metastatic disease, although this particularly comprised non-functioning tumors and no metastatic insulinomas were

included. A high IGFBP3 mRNA expression was also identified in PanNETs of the metastasis-like primary PanNET subtype in a recent genomic analysis (Scarpa *et al.* 2017).

In conclusion, our observations suggest that insulinomas are characterized by high expression levels of IGF signaling pathway components, with a possibility of a strong autocrine loop especially in benign well-differentiated insulinomas. This IGF-signaling pathway appears to be downregulated during tumor progression, coinciding with a shorter 10 years disease free survival.

Funding

This study was supported by The Dutch Digestion Foundation (MLDS, WO06-25) (to EJS). A. Perren was supported by Swiss Cancer League (KFS 3360-02-2014) and SNF (310030-144236)

Acknowledgements

The authors thank Prof. Dr. A. Driessen for her support in classification of the NETS, Dr. M. Gielen and Dr. J. Derks for advice regarding statistical evaluation of the data, Prof. Dr. P.E. Goretzki for providing tissue samples and F. Dogan for technical assistance with part of the qRT-PCR assays.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

499 **References**

- 500 Allison AS, McIntyre MA, McArdle C & Habib FK 2007 The insulin-like growth factor type 1
501 receptor and colorectal neoplasia: insights into invasion. *Hum Pathol* **38** 1590-1602.
- 502 Alvino CL, Ong SC, McNeil KA, Delaine C, Booker GW, Wallace JC & Forbes BE 2011
503 Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor
504 activation by IGF-II. *PLoS One* **6** e27488.
- 505 Baxter RC 2014 IGF binding proteins in cancer: mechanistic and clinical insights. *Nat Rev*
506 *Cancer* **14** 329-341.
- 507 Bergman D, Halje M, Nordin M & Engstrom W 2013 Insulin-like growth factor 2 in
508 development and disease: a mini-review. *Gerontology* **59** 240-249.
- 509 Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, Kleeff J,
510 Herpel E, Ehemann V *et al.* 2009 Expression pattern and functional relevance of
511 epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets
512 in pancreatic endocrine tumors? *Am J Gastroenterol* **104** 171-181.
- 513 Cao Y, Gao Z, Li L, Jiang X, Shan A, Cai J, Peng Y, Li Y, Jiang X, Huang X *et al.* 2013
514 Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. *Nat*
515 *Commun* **4** DOI: 10.1038/ncomms3810.
- 516 Cerrato F, Sparago A, Verde G, De Crescenzo A, Citro V, Cubellis MV, Rinaldi MM,
517 Boccuto L, Neri G, Magnani C *et al.* 2008 Different mechanisms cause imprinting defects
518 at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. *Hum Mol*
519 *Genet* **17** 1427-1435.
- 520 Chao W & D'Amore PA 2008 IGF2: epigenetic regulation and role in development and
521 disease. *Cytokine Growth Factor Rev* **19** 111-120.
- 522 Ciardiello F & Tortora G 2008 EGFR Antagonists in Cancer Treatment. *New England*
523 *Journal of Medicine* **358** 1160-1174.
- 524 Cives M, Soares HP & Strosberg J 2016 Will clinical heterogeneity of neuroendocrine
525 tumors impact their management in the future? Lessons from recent trials. *Curr Opin*
526 *Oncol* **28** 359-366.
- 527 Creemers SG, van Koetsveld PM, van Kemenade FJ, Papathomas TG, Franssen GJ, Dogan
528 F, Eekhoff EM, van der Valk P, de Herder WW, Janssen JA *et al.* 2016 Methylation of IGF2
529 regulatory regions to diagnose adrenocortical carcinomas. *Endocr Relat Cancer* **23** 727-
530 737.
- 531 Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T & Yao JC 2017 Trends in the
532 Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in
533 the United States. *JAMA Oncol* DOI: **10.1001/jamaoncol.2017.0589**.
- 534 De Bruijn K, Biermann K, Shapiro J, Dogan F, Spaander M, Janssen J, Wijnhoven B,
535 Borsboom G, Hofland L & van Eijck C 2015 Absence or low IGF-1R-expression in
536 esophageal adenocarcinoma is associated with tumor invasiveness and radicality of
537 surgical resection. *J Surg Oncol* **111** 1047-1053.

- 538 Dejeux E, Olaso R, Dousset B, Audebourg A, Gut IG, Terris B & Tost J 2009
539 Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in
540 insulinomas leading to loss-of-imprinting and overexpression. *Endocr Relat Cancer* **16**
541 939-952.
- 542 Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J,
543 Zhao L *et al.* 2015 Insulin-like growth factor (IGF) signaling in tumorigenesis and the
544 development of cancer drug resistance. *Genes Dis* **2** 13-25.
- 545 Falletta S, Partelli S, Rubini C, Nann D, Doria A, Marinoni I, Polenta V, Di Pasquale C,
546 Degli Uberti E, Perren A *et al.* 2016 mTOR inhibitors response and mTOR pathway in
547 pancreatic neuroendocrine tumors. *Endocr Relat Cancer* **23** 883-891.
- 548 Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK & Janson ET 2003 Expression of
549 molecular targets for tyrosine kinase receptor antagonists in malignant endocrine
550 pancreatic tumors. *Clin Cancer Res* **9** 1469-1473.
- 551 Garraway LA & Janne PA 2012 Circumventing cancer drug resistance in the era of
552 personalized medicine. *Cancer Discov* **2** 214-226.
- 553 Gentzler RD, Altman JK & Plataniias LC 2012 An overview of the mTOR pathway as a
554 target in cancer therapy. *Expert Opin Ther Targets* **16** 481-489.
- 555 Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L & Coppola D 2010 Activation of
556 the serine/threonine protein kinase Akt in enteropancreatic neuroendocrine tumors.
557 *Anticancer Res* **30** 5063-5067.
- 558 Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH & Ames MM 2013
559 Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
560 *Pancreas* **42** 411-421.
- 561 Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ & Maitra A 2004 Met proto-
562 oncogene and insulin-like growth factor binding protein 3 overexpression correlates with
563 metastatic ability in well-differentiated pancreatic endocrine neoplasms. *Clin Cancer Res*
564 **10** 6152-6158.
- 565 Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R,
566 Mahoney M & Erlichman C 2006 A phase II trial of gefitinib in patients (pts) with
567 progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C)
568 study. *ASCO Meeting Abstracts* **24** 4043.
- 569 Hoog A, Kjellman M, Nordqvist AC, Hoog CM, Juhlin C, Falkmer S, Schalling M &
570 Grimelius L 2001 Insulin-like growth factor-II in endocrine pancreatic tumours.
571 Immunohistochemical, biochemical and in situ hybridization findings. *APMIS* **109** 127-
572 140.
- 573 Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH,
574 Wolfgang CL, Choti MA *et al.* 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are
575 frequently altered in pancreatic neuroendocrine tumors. *Science* **331** 1199-1203.
- 576 Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de Herder W, de Krijger RR,
577 Verhofstad AA, Hermus AR, Kummer JA *et al.* 2007 DNA copy number status is a
578 powerful predictor of poor survival in endocrine pancreatic tumor patients. *Endocr Relat*
579 *Cancer* **14** 769-779.

- 580 Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M,
581 Denkert C, Rocken C, Wiedenmann B *et al.* 2011 mTOR expression and activity patterns
582 in gastroenteropancreatic neuroendocrine tumours. *Endocr Relat Cancer* **18** 181-192.
- 583 Komori Y, Yada K, Ohta M, Uchida H, Iwashita Y, Fukuzawa K, Kashima K, Yokoyama S,
584 Inomata M & Kitano S 2014 Mammalian target of rapamycin signaling activation patterns
585 in pancreatic neuroendocrine tumors. *J Hepatobiliary Pancreat Sci* **21** 288-295.
- 586 Kuklinski A, Kamocki Z, Koda M, Piotrowski Z, Sulkowski S, Lesniewicz R, Pawlak K,
587 Mysliwiec P & Kedra B 2011 IGF-IR in patients with advanced colorectal cancer in
588 correlation with certain clinico-morphological factors: Initial report. *Oncol Lett* **2** 1155-
589 1159.
- 590 Livingstone C 2013 IGF2 and cancer. *Endocr Relat Cancer* **20** R321-339.
- 591 Lodhia KA, Tienchaiananda P & Haluska P 2015 Understanding the Key to Targeting the
592 IGF Axis in Cancer: A Biomarker Assessment. *Front Oncol* **5** DOI:
593 10.3389/fonc.2015.00142
- 594 Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo
595 R, Tofanetti FR, Mameli MG *et al.* 2009 High coexpression of both insulin-like growth
596 factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated
597 with shorter disease-free survival in resected non-small-cell lung cancer patients. *Ann*
598 *Oncol* **20** 842-849.
- 599 Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, Ahmad S,
600 Radhakrishnan A, Barbhuiya MA, Kumar RV *et al.* 2013 Identification of head and neck
601 squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell
602 secretome. *Biochim Biophys Acta* **1834** 2308-2316.
- 603 Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S,
604 Speel EJ & Perren A 2014 Loss of DAXX and ATRX are associated with chromosome
605 instability and reduced survival of patients with pancreatic neuroendocrine tumors.
606 *Gastroenterology* **146** 453-460 e455.
- 607 Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso
608 G, Di Florio A, delle Fave G *et al.* 2010 Pancreatic endocrine tumors: expression profiling
609 evidences a role for AKT-mTOR pathway. *J Clin Oncol* **28** 245-255.
- 610 Muniraj T, Vignesh S, Shetty S, Thiruvengadam S & Aslanian HR 2013 Pancreatic
611 neuroendocrine tumors. *Dis Mon* **59** 5-19.
- 612 Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR
613 & Berchuck A 2006 Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2
614 expression in epithelial ovarian cancer. *Mol Cancer Res* **4** 283-292.
- 615 Oberg K 2012 Neuroendocrine tumors of the digestive tract: impact of new classifications
616 and new agents on therapeutic approaches. *Curr Opin Oncol* **24** 433-440.
- 617 Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM & Lloyd RV
618 2005 Epidermal growth factor receptor and activated epidermal growth factor receptor
619 expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. *Mod*
620 *Pathol* **18** 1329-1335.

- 621 Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU & Eng C
 622 2000 Mutation and expression analyses reveal differential subcellular
 623 compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet
 624 cells. *Am J Pathol* **157** 1097-1103.
- 625 Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T,
 626 Brais LK, Daskalova A, Heafield R *et al.* 2013 Prognostic significance of MTOR pathway
 627 component expression in neuroendocrine tumors. *J Clin Oncol* **31** 3418-3425.
- 628 Rajapaksha H & Forbes BE 2015 Ligand-Binding Affinity at the Insulin Receptor Isoform-A
 629 and Subsequent IR-A Tyrosine Phosphorylation Kinetics are Important Determinants of
 630 Mitogenic Biological Outcomes. *Front Endocrinol (Lausanne)* **6** 107.
- 631 Ren Z, Shin A, Cai Q, Shu XO, Gao YT & Zheng W 2007 IGFBP3 mRNA expression in
 632 benign and malignant breast tumors. *Breast Cancer Res* **9** DOI: 10.1186/bcr1634.
- 633 Robbins HL & Hague A 2015 The PI3K/Akt Pathway in Tumors of Endocrine Tissues. *Front*
 634 *Endocrinol (Lausanne)* **6** DOI: 10.3389/fendo.2015.00188.
- 635 Sadanandam A, Wulschlegel S, Lyssiotis CA, Grotzinger C, Barbi S, Bersani S, Korner J,
 636 Wafy I, Mafficini A, Lawlor RT *et al.* 2015 A Cross-Species Analysis in Pancreatic
 637 Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic,
 638 Developmental, and Metabolic Characteristics. *Cancer Discov* **5** 1296-1313.
- 639 Samani AA, Yakar S, LeRoith D & Brodt P 2007 The role of the IGF system in cancer
 640 growth and metastasis: overview and recent insights. *Endocr Rev* **28** 20-47.
- 641 Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller
 642 DK, Mafficini A *et al.* 2017 Whole-genome landscape of pancreatic neuroendocrine
 643 tumours. *Nature* **543** 65-71.
- 644 Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J & Mayer D 2000 Down-regulation of
 645 insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in
 646 advanced human breast cancer. *Int J Cancer* **89** 506-513.
- 647 Srivastava A, Alexander J, Lomakin I & Dayal Y 2001 Immunohistochemical expression of
 648 transforming growth factor alpha and epidermal growth factor receptor in pancreatic
 649 endocrine tumors. *Hum Pathol* **32** 1184-1189.
- 650 Takahash M, Papavero V, Yuhas J, Kort E, Kanayama HO, Kagawa S, Baxter RC, Yang
 651 XMJ, Gray SG & Teh BT 2005 Altered expression of members of the IGF-axis in clear cell
 652 renal cell carcinoma. *Int J Oncol* **26** 923-931.
- 653 Weroha SJ & Haluska P 2012 The insulin-like growth factor system in cancer. *Endocrinol*
 654 *Metab Clin North Am* **41** 335-350.
- 655 Wulbrand U, Wied M, Zofel P, Goke B, Arnold R & Fehmann H 1998 Growth factor
 656 receptor expression in human gastroenteropancreatic neuroendocrine tumours. *Eur J Clin*
 657 *Invest* **28** 1038-1049.
- 658 Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R & Fehmann HC 2000 mRNA
 659 expression patterns of insulin-like growth factor system components in human
 660 neuroendocrine tumours. *Eur J Clin Invest* **30** 729-739.

661 Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A & Ju J 2006 Association of insulin-like
662 growth factor binding protein-3 expression with melanoma progression. *Mol Cancer Ther*
663 **5** 3078-3084.

664 Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T,
665 Capdevila J, de Vries EG *et al.* 2011 Everolimus for advanced pancreatic neuroendocrine
666 tumors. *N Engl J Med* **364** 514-523.

667 Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner
668 H, Voi M *et al.* 2016 Everolimus for the treatment of advanced, non-functional
669 neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised,
670 placebo-controlled, phase 3 study. *Lancet* **387** 968-977

671 Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L & Guo JC 2012 Activated
672 mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. *J Surg Oncol*
673 **106** 972-980.

674

675

676

Legends to the figures

Figure 1. Representative examples of immunohistochemical EGFR, pAKT, pERK, IGF2, IGF1R and INSR protein expression in human tissue: normal pancreas (B, D, G, J, M), a premalignant laryngeal lesion (A) and insulinomas (C, E, F, H, I, K, L, N, O). Strong membranous EGFR expression in a premalignant laryngeal lesion (A), weakly positive expression in normal acinar cells, and no detectable expression in the islets (B) and in insulinomas (C). Moderate to strong nuclear p-AKT expression in normal pancreatic islets (D), and moderate to strong nuclear and moderate cytoplasmic expression in an insulinoma (E). Strong nuclear p-ERK immunostaining in an insulinoma (F). Strong aggregate like, extracellular IGF2 localization in normal acinar cells, and a moderate, diffuse granular cytoplasmic staining pattern in pancreatic islets (G). Strong, granular cytoplasmic IGF2 expression in a non-metastatic insulinoma and weakly positive, diffuse cytoplasmic expression in a metastatic insulinoma (H and I respectively). Strongly positive, membranous IGF1R expression in normal acinar cells and moderately positive, granular cytoplasmic expression pattern in islet cells (J). In insulinomas a strong, cytoplasmic expression (K) or combined cytoplasmic and membranous IGF1R expression pattern (L) is seen. Moderate to strong cytoplasmic, perinuclear INSR expression in normal acinar cells with a granular, cytoplasmic pattern in islet cells (M). Moderate, diffuse granular and strong perinuclear INSR expression (N) or weak to moderate, diffuse expression (O) in insulinomas. Original magnifications 200X.

Figure 2. Representative examples of immunohistochemical p-S6K and p-4EBP1 protein expression in normal human pancreatic tissue and insulinomas. Strong, perinuclear expression pattern of p-S6K in normal acinar cells, while the islets cells show a very weak, diffuse cytoplasmic expression (A). Weak cytoplasmic and moderate to strong nuclear expression of p-S6K in insulinoma (B). Moderately to strongly positive diffuse cytoplasmic and nuclear p-4EBP1 immunostaining in normal exocrine pancreas cells at the periphery of a lobule (C). No detectable p-4EBP1 expression in normal pancreatic islet (D). Strong nuclear and weak to moderate cytoplasmic p-4EBP1 expression in tumor

29 adjacent exocrine tissue (E). Moderate to strong nuclear and weak cytoplasmic p-4EBP1
30 expression in insulinoma (F).

31

32 **Figure 3.** Kaplan-Meier analysis showing 10 year disease-free survival rates of
33 insulinoma patients with regard to mRNA expression (A-D) and clinicopathological
34 parameters (E-H). . Correlation between survival and mRNA expression, A: *INS* (cut off
35 25th percentile), B: *IGF1R* (cut off 25th percentile), C: *INSR-A* (cut off 25th percentile), D:
36 *IGFBP3* (cut off 25th percentile), E: Grade (Grade1 versus Grade 2+3), F: Disease (non-
37 metastatic versus metastatic), G: Tumor size (<2 cm versus ≥2 cm) and H: Disease
38 stage (Stage I+IIa versus IV).

39 Dotted lines in plot A-D refer to low expression.

40

41 **Figure 4.** Kaplan-Meier analysis showing 10 year disease-free survival rates of
42 insulinoma patients with regard to protein expression (A-C) and clinicopathological
43 parameters (D-G). Correlation between survival and protein expression, A: IGF2
44 (moderate (2) vs high (3) expression), B: cytoplasmic IGF1R (low vs high expression), C:
45 cytoplasmic INSR (low vs high expression), D: Grade (Grade1 versus Grade 2+3), E:
46 Disease (non-metastatic versus metastatic), F: Tumor size (<2 cm versus ≥2 cm) and G:
47 Disease stage.

48

49 **Suppl. Figure 1.** Control immunoperoxidase stainings for p-AKT, p-ERK, p-S6K
50 and p4-EBP1. Moderate to strong nuclear and weak cytoplasmic expression of p-AKT (A)
51 and
52 moderate nuclear expression of p-ERK (B) in a lung tumor harboring a
53 K-ras exon 2 mutation. Moderate nuclear p-S6K expression (C) and moderate
54 cytoplasmic p-4EBP1 expression (D) in glandular normal colon cells .
55 A low percentage of cells also shows a moderate to strong nuclear p-4EBP1
56 staining pattern (D). Original magnifications 200X.

Suppl. Figure 2. Kaplan-Meier analysis showing 10 year overall survival rates of insulinoma patients with regard to mRNA expression (A-D) and clinicopathological parameters (E-H). Correlation between survival and mRNA expression, A: INS (cut off 25th percentile), B: IGF1R (cut off 25th percentile), C: INSR-A (cut off 25th percentile), D: IGFBP3 (cut off 25th percentile), E: Grade (Grade1 versus Grade 2+3), F: Disease (non-metastatic versus metastatic) G: Tumor size (<2 cm versus \geq 2 cm) and H: Disease stage (Stage I+IIa versus IV). Dotted lines in plots A-D refer to low expression.

Suppl. Figure 3. Kaplan-Meier analysis showing 10 year overall survival rates of insulinoma patients with regard to protein expression (A-C) and clinicopathological parameters (D-G). Correlation between survival and protein expression, A: IGF2 (moderate (2) vs high (3) expression), B: cytoplasmic IGF1R (low vs high expression), C: cytoplasmic INSR (low vs high expression), D: Grade (Grade1 versus Grade 2+3), E: Disease (non-metastatic versus metastatic), F: Tumor size (<2 cm versus \geq 2 cm) and G: Disease stage. Dotted lines in plots A-C refer to low expression.

Table 1 Mean mRNA expression levels of neuroendocrine related genes and genes in the MAPK/ AKT and IGF pathway in 48 insulinomas

	normalised to GUSB			Relative to pancreatic islets		
	Mean	Std Dev	Median	Mean	Std Dev	Median
<i>CGA</i>	88.91	± 95.94	59,94	6.04	± 6.61	3,92
<i>SYNAPT</i>	2.28	± 1.92	1,83	4.83	± 4.31	3,61
<i>INS</i>	8351.20	± 8507.11	6269,65	2.01	± 2.03	1,48
<i>EGFR</i>	0.10	± 0.10	0,07	0.15	± 0.17	0,11
<i>AKT</i>	2.58	± 1.45	2,28	0.75	± 0.45	0,63
<i>ERK1</i>	1.10	± 0.73	0,93	1.03	± 0.64	0,95
<i>ERK2</i>	1.56	± 0.89	1,45	0.68	± 0.49	0,55
<i>IGF1</i>	0.04	± 0.13	0,01	NA		
<i>IGF1R</i>	0.11	± 0.12	0,06	0.82	± 0.92	0,49
<i>IGF2</i>	1.46	± 3.12	0,43	12.44	± 22.64	3,54
<i>IGF2R</i>	0.13	± 0.09	0,11	0.67	± 0.42	0,58
<i>IGF bp1</i>	0.03	± 0.07	0,00	1.63	± 4.13	0,16
<i>IGF bp2</i>	4.81	± 5.69	3,44	4.04	± 4.41	3,18
<i>IGF bp3</i>	0.21	± 0.32	0,09	2.86	± 4.74	1,24
<i>IGF bp6</i>	0.23	± 0.32	0,12	2.03	± 1.99	1,37
<i>INSR-A</i>	0.22	± 0.20	0,19	1.30	± 0.70	1,27
<i>INSR-B</i>	0.10	± 0.09	0,08	0.75	± 0.54	0,70
<i>mTOR</i>	0.01	± 0.01	0,01	0.35	± 0.44	0,22
<i>RPS6KB1</i>	0.02	± 0.02	0,01	0.58	± 0.61	0,39
<i>EIF4EBP1</i>	0.84	± 0.87	0,58	0.45	± 0.46	0,30

IGF1 relative to pancreatic islets cannot be calculated since *IGF1* was not detectable in normal pancreatic islets

Table 2 Immunohistochemical expression of proteins in the EGFR/MAPK/AKT/IGF/mTOR pathways in insulinomas, presented as percentage of the samples with a specified staining intensity.

Insulinomas	negative	weakly positive	positive
EGFR	100	0	0
p-AKT nuclear	60	18	22
p-AKT cytoplasmic	51	41	8
p-ERK nuclear	30	38	32
p-ERK cytoplasmic	38	38	24
IGF2	1	7	92
IGF1R cytoplasmic	4	18	78
IGF1R membranous	38	11	51
INSR cytoplasmic	4	13	83
p-S6K nuclear	72	9	19
p-S6K cytoplasmic	72	16	12
p-4EBP1 nuclear	93	3	4
p-4EBP1 cytoplasmic	78	13	9

Staining intensity was defined as negative, weakly positive in >10 % of cells and moderately or strongly positive in >10 % of cells.

Abbreviation used: p=phosphorylated

Table 3A Correlation of mRNA expression levels in insulinomas, relative to normal single donor pancreatic islet mRNA, with grade, tumor size, metastatic disease and disease stage

p-values <0.05 correspond to lower specific gene expression in tumors with higher grade, metastatic progression, larger size and more advanced disease stage

mRNA	Grade 1 vs Grade 2+3 p-Value	Non-metastatic vs metastatic p-Value	Tumor size <2cm vs ≤2 cm p-Value	Disease stage I+II vs IV p-Value
INS	NS	<0.0001	0.009	<0.0001
AKT	NS	NS	NS	NS
ERK1	NS	NS	NS	NS
ERK2	NS	NS	NS	NS
IGF2	NS	NS	NS	0.004
IGF1R	NS	NS	NS	0.024
IGF2R	0.039	NS	NS	NS
IGFBP2	NS	NS	NS	NS
IGFBP3	NS	NS	NS	NS
IGFBP6	NS	NS	NS	NS
INSR-A	NS	NS	NS	NS
INSR-B	NS	NS	NS	NS
EIF4EBP1	NS	NS	0.003	NS
RPS6KB1	NS	NS	NS	NS

NS, not significant

Table 3B Correlation of protein expression levels with grade, tumor size, metastatic disease and disease stage

p-values <0.05 correspond to lower specific protein expression in tumors with higher grade, metastatic progression, larger size and more advanced disease stage

Protein	Grade 1 vs Grade 2+3 p-Value	Non-metastatic vs metastatic p-Value	Tumor size <2cm vs >2 cm p-Value	Disease stage I+II vs IV p-Value
IGF2	NS	0.001	0.001	0.009
p-AKT nuclear	NS	NS	NS	NS
p-AKT cytoplasmic	NS	NS	NS	NS
p-ERK nuclear	NS	NS	NS	0.004
p-ERK cytoplasmic	NS	NS	NS	0.006
IGF1R cytoplasmic	NS	0.026	NS	0.021
IGF1R membranous	NS	NS	NS	NS
INSR cytoplasmic	NS	0.035	NS	NS
INSR membranous	0.004	0.004	NS	0.004
p-4EBP1 nuclear	NS	NS	NS	NS
p-4EBP1 cytoplasmic	0.001	NS	NS	NS
p-PS6K cytoplasmic	NS	0.030	NS	NS

NS, not significant

Abbreviation used: p = phosphorylated

Table 4 Significance levels (p-values) for univariate analysis of insulinomas, indicating the relation of clinical and molecular parameters with disease outcome for tumors subjected to **A** mRNA expression analysis and **B** protein expression analysis

A	OS p-value	DFS p-value	B	OS p-value	DFS p-value
Grade ¹	0.007	0.002	Grade ¹	<0.0001	<0.0001
Disease ²	<0.0001	<0.0001	Disease ²	<0.0001	<0.0001
Tumor size ³	0.003	<0.0001	Tumor size ³	<0.0001	<0.0001
Disease stage ⁴	<0.0001	<0.0001	Disease stage ⁴	<0.0001	<0.0001
<i>INS</i> ⁵	<0.0001 ^a	<0.0001 ^a	IGF2 ⁶	0.027 ^a	0.035 ^a
<i>IGF1R</i> ⁵	<0.0001 ^a	<0.0001 ^a	IGF1R ⁶	0.033 ^a	0.012 ^a
<i>INSR-A</i> ⁵	0.032 ^a	0.0019 ^a	INSR ⁶	0.016 ^a	0.010 ^a
<i>IGFBP3</i> ⁵	0.001 ^b	<0.0001 ^b			

Abbreviations used: OS, overall survival; DFS, disease free survival

¹ Grade 1 vs Grade 2+3; ² non-metastatic vs metastatic disease; ³ tumor size <2 cm vs ≥2 cm; ⁴ disease stage I+II vs IV; ⁵ high vs low mRNA expression (see Figure 2 A-D legend); ⁶ high vs low protein expression (see Figure 3 A-C legend).

^a p-values refer to shorter 10 years survival for lower expression; ^b p-values refer to shorter 10 years survival for higher expression

Figure 1




Figure 1

199x280mm (300 x 300 DPI)

Figure 2




Figure 2

200x119mm (300 x 300 DPI)

Figure 3




Figure 3

281x461mm (300 x 300 DPI)

Figure 4




Figure 4

279x459mm (300 x 300 DPI)